Sepsis Pipeline Forecast 2024: FDA Approvals, Therapies by DelveInsight | Roche, Pfizer Inc., GSK Plc, Viatris, Mylan, AbbVie, Allergan Pharma, Asahi Kasei Crp., RegeneRx

Posted on
by

Sepsis Pipeline Forecast 2024: FDA Approvals, Therapies by DelveInsight | Roche, Pfizer Inc., GSK Plc, Viatris, Mylan, AbbVie, Allergan Pharma, Asahi Kasei Crp., RegeneRx
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sepsis pipeline constitutes 25+ key companies continuously working towards developing 30+ Sepsis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Sepsis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sepsis Market.

 

The Sepsis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Sepsis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Sepsis treatment therapies with a considerable amount of success over the years. 

  • Sepsis companies working in the treatment market are Fe Pharmaceuticals, Revagenix, Northern Therapeutics, Recce Pharmaceuticals, Artcline GmbH, Inotrem, Shionogi, SciClone Pharmaceuticals, and others, are developing therapies for the Sepsis treatment 

  • Emerging Sepsis therapies in the different phases of clinical trials are- FEP-100, Research programme, GEM00220, RECCE 327, ARTICE therapy, Nangibotide, Cefiderocol, Thymosin alpha, and others are expected to have a significant impact on the Sepsis market in the coming years.   

  • In May 2024, A clinical trial funded by the US National Institutes of Health (NIH) suggests that intravenous acetaminophen may benefit sepsis patients. In this mid-stage trial, 447 adult sepsis patients with respiratory or circulatory organ dysfunction were enrolled. Conducted from October 2021 to April 2023, the study involved participants admitted to 40 academic hospitals across the US. They were randomly assigned to receive either intravenous acetaminophen or a placebo every six hours for five days. The primary focus was on the number of patients surviving without the need for organ support, such as mechanical ventilation or kidney failure treatment.

  • In April 2024, Enlivex Therapeutics has announced positive top-line safety and efficacy results from its Phase II clinical trial of Allocetra, an off-the-shelf cell therapy, for sepsis treatment. This placebo-controlled, randomized trial aims to identify the optimal dose of Allocetra when combined with the standard of care for sepsis caused by various infections. The study targeted patients with sepsis linked to pneumonia, biliary, urinary tract, or peritoneal infections.

  • In January 2024, Matisse Pharmaceuticals has announced positive top-line results from the HistoSeps trial, which aimed to assess the tolerability, safety, and pharmacokinetics of M6229 for sepsis treatment. Conducted at Amsterdam University Medical Center, this first-in-human trial involved ten critically ill patients and achieved its primary objectives. The trial showed favorable tolerability and safety, as well as nearly dose-proportional pharmacokinetics for six-hour intravenous (IV) administration of M6229 in these patients.

 

Sepsis Overview

Sepsis is a severe medical condition triggered by the body’s overwhelming response to infection. It can lead to tissue damage, organ failure, and potentially death if not treated promptly.

 

Get a Free Sample PDF Report to know more about Sepsis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sepsis-pipeline-insight

 

Emerging Sepsis Drugs Under Different Phases of Clinical Development Include:

  • FEP-100: Fe Pharmaceuticals

  • Research programme: Revagenix

  • GEM00220: Northern Therapeutics

  • RECCE 327: Recce Pharmaceuticals

  • ARTICE therapy: Artcline GmbH

  • Nangibotide: Inotrem

  • Cefiderocol: Shionogi

  • Thymosin alpha: SciClone Pharmaceuticals

 

Sepsis Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

 

Sepsis Molecule Type

Sepsis Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Sepsis Pipeline Therapeutics Assessment

  • Sepsis Assessment by Product Type

  • Sepsis By Stage and Product Type

  • Sepsis Assessment by Route of Administration

  • Sepsis By Stage and Route of Administration

  • Sepsis Assessment by Molecule Type

  • Sepsis by Stage and Molecule Type

 

DelveInsight’s Sepsis Report covers around 30+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Sepsis product details are provided in the report. Download the Sepsis pipeline report to learn more about the emerging Sepsis therapies

 

Some of the key companies in the Sepsis Therapeutics Market include:

Key companies developing therapies for Sepsis are – F. Hoffmann-La Roche Ltd, Pfizer Inc., GSK Plc, Viatris Inc. (Mylan Inc.), AbbVie Inc (Allergan Pharmaceuticals Private Limited), Asahi Kasei Corporation, RegeneRx, Inotrem SAEndacea Inc., Adrenomed AG, and others.

 

Sepsis Pipeline Analysis:

The Sepsis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sepsis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sepsis Treatment.

  • Sepsis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Sepsis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sepsis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Sepsis drugs and therapies

 

Sepsis Pipeline Market Drivers

  • Increase in awareness of Sepsis, increase in the Research and Development activities are some of the important factors that are fueling the Sepsis Market.

 

Sepsis Pipeline Market Barriers

  • However, side effects associated with the treatment, economic burden associated with the disease and other factors are creating obstacles in the Sepsis Market growth.

 

Scope of Sepsis Pipeline Drug Insight    

  • Coverage: Global

  • Key Sepsis Companies: Fe Pharmaceuticals, Revagenix, Northern Therapeutics, Recce Pharmaceuticals, Artcline GmbH, Inotrem, Shionogi, SciClone Pharmaceuticals, and others

  • Key Sepsis Therapies: FEP-100, Research programme, GEM00220, RECCE 327, ARTICE therapy, Nangibotide, Cefiderocol, Thymosin alpha, and others

  • Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies

  • Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers 

 

Request for Sample PDF Report for Sepsis Pipeline Assessment and clinical trials

 

Table of Contents

1. Sepsis Report Introduction

2. Sepsis Executive Summary

3. Sepsis Overview

4. Sepsis- Analytical Perspective In-depth Commercial Assessment

5. Sepsis Pipeline Therapeutics

6. Sepsis Late Stage Products (Phase II/III)

7. Sepsis Mid Stage Products (Phase II)

8. Sepsis Early Stage Products (Phase I)

9. Sepsis Preclinical Stage Products

10. Sepsis Therapeutics Assessment

11. Sepsis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sepsis Key Companies

14. Sepsis Key Products

15. Sepsis Unmet Needs

16 . Sepsis Market Drivers and Barriers

17. Sepsis Future Perspectives and Conclusion

18. Sepsis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services